Endotoxin requirements for alveolar macrophage stimulation.
Acute pulmonary failure or ARDS in severely injured patients continues to be a significant problem. The most important clinical risk factor identified is sepsis syndrome. Sepsis syndrome is the clinical correlate of a malignant systemic inflammatory process and is directed in large part by the tissue-fixed macrophage (M phi), such as the alveolar M phi. The M phi is capable of producing most of the central inflammatory mediators responsible for the pathophysiology seen during sepsis and organ injury. Two major mediators are procoagulant activity (PCA), leading to diffuse microvascular thrombosis, and tumor necrosis factor (TNF), causing much of the physiologic derangement of sepsis. Endotoxins (LPS) derived from Gram-negative bacterial cell walls are the primary inflammatory stimulus for the tissue-fixed M phi production of inflammatory mediators. It is not completely known how LPS interacts with its various cellular targets, but it is hoped that knowledge of the molecular interactions involved in stimulation of the M phi by endotoxin will lead to therapies to modulate the response and prevent deleterious processes such as ARDS. In the present studies, LPS from E. coli 0111:B4 was shown in a dose response to stimulate large levels of both PCA and TNF in alveolar M phi. LPS from Bacteroides fragilis and Lipid X (the monosaccharide precursor of endotoxin) were unable to cause stimulation of the M phi in vitro. However, both moieties, B. fragilis LPS and Lipid X, were able to effectively and specifically compete with E. coli LPS and block M phi stimulation.(ABSTRACT TRUNCATED AT 250 WORDS)
Maier
R V
RV
Department of Surgery, Harborview Medical Center, Seattle, WA 98104.
Hahnel
G B
GB
Pohlman
T H
TH
D000818:Animals; D001441:Bacteroides fragilis; D001779:Blood Coagulation Factors / Q000096:biosynthesis; D002478:Cells, Cultured; D004731:Endotoxins / Q000494:pharmacology*; D004926:Escherichia coli; D006017:Glycolipids / Q000378:metabolism; D006801:Humans; D008070:Lipopolysaccharides / Q000378:metabolism; D008262:Macrophage Activation; D008264:Macrophages / Q000187:drug effects* / Q000502:physiology; D008297:Male; D009102:Multiple Organ Failure / Q000209:etiology* / Q000503:physiopathology; D011650:Pulmonary Alveoli / Q000187:drug effects* / Q000378:metabolism; D011817:Rabbits; D012128:Respiratory Distress Syndrome / Q000209:etiology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D001779:Blood Coagulation Factors; D004731:Endotoxins; D006017:Glycolipids; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; C045072:macrophage procoagulant activity; C044283:lipid X